



Who are the most influential people in vaccines?

TOP 50 vaccine influencers

Who are the most influential people in the global vaccines world?

This is the question we asked our blog subscribers, LinkedIn group members and anyone in our contact network to compile a comprehensive list of the Top 50 as named by you.

The following 50 personalities were picked based on their career achievements whether this was groundbreaking discovery and research or innovation, funding, lifetime dedication or simply because they might have inspired others to do well. It is great to see that we have representatives from all aspects including industry, governments, philanthropy, academia and even showbiz.

Thank you to everyone who has helped us compile the list and please feel free to share it with your colleagues.

50



Ewan McGregor,
Actor and **UNICEF Ambassador**

Ewan McGregor is on a mission to the ends of the earth to immunise some of the hardest-to-reach children in the world, following two vaccine trails, or 'cold chains', supported by Unicef.

49



Rajeev Venkayya,
Executive Vice President, Vaccine
Business Division,
Takeda

Dr. Venkayya is the Executive Vice President, Vaccine Business at Takeda Pharmaceuticals International, overseeing Takeda's global vaccine enterprise. Prior to this he was the Director of Vaccine Delivery at the Bill & Melinda Gates Foundation, where he was responsible for the foundation's top two priorities of polio eradication and new vaccine introduction, and investments of approximately \$500 million/year. Dr. Venkayya was previously the Special Assistant to the President and Senior Director for Biodefense at the White House.

48



Filip Dubovsky,
Vice-President Clinical Development
Vaccines and Infectious Disease,
MedImmune

Dr. Filip Dubovsky joined MedImmune in August 2006 as director, clinical development and was named vice president, clinical development, and global clinical therapeutic head, vaccines in July 2008. In this capacity, he leads the vaccine clinical development programs and the vaccine clinical activities for MedImmune's influenza franchise. Prior to joining MedImmune, Dr. Dubovsky held several roles of increasing responsibility in support of the Malaria Vaccine Initiative, PATH.

47



Jon Kim Andrus,
Chief, Immunization Unit
Pan American Health Organization

Dr. Jon Kim Andrus, a public health expert with 25 years of experience of working in the field of vaccines, immunization, and primary care in developing countries, has been named deputy director of the Pan American Health Organization, Regional Office for the Americas of the World Health Organization (PAHO/WHO). Dr. Andrus has been serving as lead senior technical advisor for PAHO's immunization program, where he has been a forceful advocate for spreading the benefits of vaccination.

46



Pierre Morgon,
Vice President, Franchise & Global
Marketing Strategy
Sanofi Pasteur

Pierre Morgon has over 25 years experience in the pharmaceutical industry, in marketing and operations positions as Product Manager, International Group Product Manager, International Marketing Director, Vice President Marketing, VP Business Unit, General Manager and VP Global Marketing Operations. Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology) and many geographies.

45



Thomas Breuer,
Senior Vice President, Head of
Global Vaccine Development
GSK Biologicals

Accountable for Department of 1200 people, covering Clinical R&D (phase I-IV), Epidemiology & Health Economics, Safety (Qualified Person Pharmacovigilance), Medical Governance activities (including Medical Compliance) as lead physician (CMO) for Biologicals and regional Medical Affairs activities.

44



Dr Jean-Marie Okwo-Bele,
Director of Immunization, Vaccines
and Biologicals,
WHO

Dr Jean-Marie Okwo-Bele is responsible for strategic direction, coordination and management of normative and programmatic immunization activities.

During his 27 years in public health, Dr Okwo-Bele worked at country, regional and global levels in support of the expansion of childhood immunization programmes, contributing to policy formulation, capacity building, programme planning and evaluation, and disease surveillance.


43



Jerald Sadoff,
Chief Medical Officer,
Crucell

Before joining Crucell Dr. Sadoff was the President and Chief Executive Officer of Aeras Global TB Vaccine Foundation. While at Aeras, Dr. Sadoff developed the world's leading portfolio of TB vaccine candidates, with two of the four candidates currently being tested in Africa in Phase IIB efficacy trials, built a strong network of development partnerships, and created a world-class vaccine manufacturing infrastructure. Prior to jAeras Dr. Sadoff was the Executive Director of Clinical Development of Vaccines at Merck.

42



Peter Hotez,
President,
Sabin Vaccine Institute

Dr. Peter Hotez leads the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development based at the Baylor College of Medicine in Houston. His academic research focuses on vaccine development for a wide range of neglected tropical diseases around the globe, as well as studies to increase awareness about the neglected tropical diseases in developing countries and in the United States.

41



Pedro Alonso,
Director,
**Institute for Global Health of
Barcelona (ISGlobal)**

Dr. Pedro Alonso started his career in International Health 25 years ago as a physician working in West Africa. Since then his work has focused in the key determinants of morbidity and mortality in the two most vulnerable population groups in Africa: young children and pregnant women. Some of his most relevant work has been carried out in malaria, leading to the development and testing of new control tools for the prevention or treatment of *P. falciparum*. He has published more than 200 papers in international peer reviewed journals.

40



Stephen Cochi,
Senior Advisor to the Director,
CDC Center for Global Health (CGH)

Stephen L. Cochi, MD, MPH, is Senior Advisor to the Director, CDC Center for Global Health (CGH), on Immunization and the Global Health Initiative, in addition to continuing his role as Senior Advisor to the Director, Global Immunization Division, National Center for Immunization and Respiratory Diseases.

39



Julie Gerberding,
President,
Merck Vaccines

Dr. Julie Gerberding leads the company's \$5 billion global vaccine business. She is responsible for the commercialization of the current portfolio of vaccines, planning for the introduction of vaccines from the company's robust vaccine pipeline, and accelerating Merck's on-going efforts to broaden access to its vaccines in the developing world. Dr. Gerberding led the Centers for Disease Control and Prevention (CDC) as director from 2002 to 2009. During her tenure at CDC, Dr. Gerberding led the agency during more than 40 emergency response initiatives.

38



Paulo Ernani Gadelha Vieira,
President,
Oswaldo Cruz Foundation (Fiocruz)

Bill Gates is co-chair of the Bill & Melinda Gates Foundation. Along with co-chair Melinda Gates, he shapes and approves grantmaking strategies, advocates for the foundation's issues, and helps set the overall direction of the organization. Bill and Melinda Gates work together to expand opportunity to the world's most disadvantaged people by collaborating with grantees and partners.

37



Anthony Ford Hutchinson,
(ex) Executive Vice President,
Merck

He has spent 30 years at Merck, starting in 1981 when he joined Merck Frosst Canada in Montreal, where he spent 17 years moving from Director of Pharmacology to Senior Vice President and Site Head.

In 1998, Tony moved to Pennsylvania to head the basic research effort in the USA and worldwide, covering all therapeutic areas. As an Executive Vice President he became responsible for franchise strategies in multiple disease areas, including Vaccines and Infectious Diseases.

36



Jos Vandelaer,
Chief of Immunization,
UNICEF

Dr. Jos Vandelaer leads strategy development and program management and coordination. Dr. Vandelaer has been working in immunization since 1996.

Dr. Vandelaer has served as a Senior Health Specialist as a Global-level WHO focal point for the Neonatal Tetanus Elimination program. He also advised on immunization issues that included policy and strategy development, and provided scientific advice.

Prior to that, Dr. Vandelaer had served in WHO as a Medical Officer in India, Philippines, and Myanmar.

35



Christian Loucq,
Director General,
International Vaccine Institute

Dr. Loucq has over 30 years of professional experience in medicine, vaccines, pharmaceuticals, and global health globally. In addition, he managed vaccine businesses in China, India and Thailand, and worked with vaccine companies such as GlaxoSmithKline and Sanofi Pasteur, and biotechnology companies such as Rhein Biotech and Acambis. Most recently, Dr. Loucq was the Director of the Malaria Vaccine Initiative (MVI), a product development partnership based at PATH in the U.S.

34



Christopher Elias,
President, Global Development,
Bill & Melinda Gates Foundation

Dr. Chris Elias leads the foundation's efforts in integrated and innovative delivery, finding creative new ways to ensure solutions and products get into the hands of people in developing countries who need them most. Dr. Elias most recently served as the president and CEO of PATH, dedicated to improving the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors. Elias currently serves on various advisory boards, including the Nike Foundation and the Duke Global Health Institute.

33



Wayne Koff,
Senior Vice President and CSO,
International Vaccine AIDS
Initiative

Wayne C. Koff is an internationally recognized leader in AIDS vaccine research and development. He has been honored twice by the United States Department of Health and Human Services with the Special Act of Service Award for developing innovative strategies to accelerate the development of AIDS vaccines. He oversees IAVI's programs in AIDS vaccine research, discovery and development. Prior to joining IAVI, Wayne served between 1992 and 1998 as vice president, Vaccine Research and Development at United Biomedical, Inc., where he was responsible for the vaccine R&D program.

32



Manica Balasegaram,
Executive Director,
MSF Access Campaign

MSF's Access Campaign has been working to help MSF medical teams get access to affordable and effective medicines, suited to the environments where we operate, for well over a decade now.

Over ten years on and our medical teams still face the same kind of medical challenges daily, in treating people with drugs, tests and vaccines that aren't ideal or suited to the environments where they live. MSF's Access Campaign continues to work with MSF teams in the field to identify the problems and work to overcome them.

31



Norman Baylor,
President & CEO,
Biologics Consulting Group

Dr. Norman W. Baylor was formerly the Director of the Office of Vaccines Research and Review (OVRR) in the Food and Drug Administration's Center for Biologics Evaluation and Research. Prior to his position as Director, Dr. Baylor served as Deputy Director of OVRR and Associate Director for Regulatory Policy. He has evaluated and facilitated the development and licensure of numerous new vaccines such as acellular pertussis, varicella, pneumococcal conjugate, human papillomavirus (HPV), influenza, Zoster and all of the new generation combination vaccines during his 20 year career at FDA.

30



Barton Haynes,
Director of the Human Vaccine
Institute ,
Duke University School of Medicine

Barton Ford Haynes is a U.S. physician and immunologist and is internationally recognized for work in T-cell immunology, retrovirology and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the Director of the Duke Human Vaccine Institute and the Center for HIV/AIDS Vaccine Immunology (CHAVI) funded by the NIAID in 2005. He leads the Haynes Vaccine Discovery Consortia as part of the Collaboration for AIDS Vaccine Discovery (CAVD) funded by the Bill and Melinda Gates Foundation in 2006.

29



Peter Paradiso,
(ex) Vice President, New Business
and Scientific Affairs,
Pfizer

Peter R. Paradiso, recently retired as Vice President, New Business and Scientific Affairs for Pfizer Vaccines, a Division of Pfizer. In this position, he was responsible for global scientific affairs and strategic planning within the vaccine research and development group and for commercial oversight of products in development. He has worked in the field of vaccine development for the past 28 years. Dr. **Paradiso** has published broadly in the field of pediatric vaccines, especially in the areas of glycoconjugates, combination vaccines and respiratory viral vaccines.

28



Ian Frazer,
CEO & Director of Research,
Translational Research Institute

Ian Hector Frazer is the CEO and Director of Research of the Translational Research Institute. In parallel with researchers at the National Cancer Institute, Georgetown University, and University of Rochester, Frazer and his colleagues developed and patented the basic technology behind the HPV vaccine against cervical cancer; the second cancer preventing vaccine, and the first vaccine designed to prevent a cancer.

27



George Siber,
Executive Chairman,
Genocea

Dr. Siber, most recently Executive Vice President and Chief Scientific Officer of Wyeth Vaccines, is a leading authority on vaccines. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar[®]. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute.

26



Orin Levine,
Director of Vaccine Delivery,
Bill & Melinda Gates Foundation

Dr. Orin Levine is Director of Vaccine Delivery at the Bill and Melinda Gates Foundation, where he leads the Foundation's efforts to accelerate the introduction of new vaccines and related technologies and to improve routine immunization systems. He is the Foundation's focal point for engagement with the GAVI Alliance, whose mission is saving children's lives by increasing access to immunization in poor countries. Before that he was Executive Director of IVAC and Professor of International Health at the Johns Hopkins Bloomberg School of Public Health.

25



Gregory Poland,
Director,
Mayo Clinic

Dr. Gregory Poland is the Director of Mayo Clinic's Vaccine Research Group – a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response, vaccine policy, and novel vaccines important to public health. Dr. Poland is a Professor of Medicine and Infectious Diseases, the Director of the Immunization Clinic and the Director of the Program in Translational Immunovirology and Biodefense at the Mayo Clinic. He is the Editor-in-Chief for the journal "Vaccine."


24



William Foege,
Epidemiologist

William H. Foege is an epidemiologist who worked in the successful campaign to eradicate smallpox in the 1970s. Dr. Foege became Chief of the Centers for Disease Control and Prevention (CDC) Smallpox Eradication Program, and was appointed director of CDC in 1977.

23



Anthony Fauci,
Director,
NIAID

Anthony S. Fauci is an immunologist who has made substantial contributions to research in the areas of HIV/AIDS and other immunodeficiencies, both as a scientist and as the head of the NIAID. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism.

22



Ashley Birkett,
Director R&D, Malaria Vaccine,
PATH

Ashley Birkett directs the identification of promising malaria-vaccine technologies and implementation of development partnerships with for-profit and non-profit partners in alignment with MVI's research and development (R&D) strategy. In addition to leading the R&D Unit, he leads MVI's transmission-blocking vaccine (TBV) program focused on the development of malaria vaccines that reduce malaria transmission to support future elimination efforts.

21



Stephen Hoffman,
Founder, CEO & CSO,
Sanaria

Dr Hoffman is the Founder, and Chief Executive and Scientific Officer of Sanaria Inc., a company dedicated to developing a whole sporozoite malaria vaccine. From 1987-2001 he was Director of the Malaria Program at the Naval Medical Research Center where he and his team were leaders in the sequencing of the *Plasmodium falciparum* genome and conducted the first studies in the world that showed that DNA vaccines elicited killer T cells in humans.

20



Chris Viehbacher,
CEO,
Sanofi

Since December 2008, he has held the position of Chief Executive Officer, Sanofi and is a Board member, in addition to being a member of the Strategy Committee. He is also Chairman of Genzyme, which Sanofi acquired in February 2011. Christopher started his career in finance at PriceWaterhouseCoopers and joined GlaxoSmithKline (GSK) in 1988. Throughout the next 20 years with the company, he acquired broad international experience in Europe, in the United States and in Canada.

19



Craig Venter,
Founder, Chairman & CEO,
J Craig Venter Institute

J. Craig Venter, Ph.D., is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. He is Founder, Chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 300 scientists and staff dedicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics.

18



Jean Stéphane,
(ex) Chairman and President,
GSK Biologicals

Jean Stéphane was until recently Member of the Corporate Executive Team of GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in Wavre, Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of BESIX, IBA and BioWin, and as Director of BNP Paribas Fortis, VBO/FEB, Groupe Bruxelles Lambert (GBL), and Vesalius Biocapital.

17



Wayne Pisano,
President & CEO,
Vaxinnate

Wayne Pisano joined VaxInnate as interim Chief Executive Officer in January 2012 and as permanent CEO in April 2012. Wayne is the former President and CEO of sanofi pasteur, the largest company entirely dedicated to vaccines. Wayne joined sanofi pasteur as Vice President, U.S. Marketing in 1997 and held positions of increasing responsibility including Head of Global Commercial Operations and Corporate Strategy. Wayne is credited with sanofi pasteur's leading worldwide role in the influenza vaccine market with approximately 50 percent of global sales.


16



David Salisbury,
Director of Immunisation,
UK Department of Health

Professor David Salisbury is responsible for the national immunisation programme. In addition to his UK responsibilities, he works extensively with the WHO on the Global Programme for Vaccines. He was Chairman of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010, is Chairman of the European Region Certification Commission for Poliomyelitis Eradication, and is a member of Polio Elimination Certification Commission for two further WHO regions.

15



Thomas Monath,
Adjunct Professor,
Harvard School of Public Health

Dr. Monath is Chief Medical Officer of Hookipa BioTech AG and Chief Technical Officer of PaxVax Inc, where he is engaged in development of new vaccines. His expertise and experience cut across discovery research, process and analytical development, manufacturing, preclinical and clinical development, and regulatory affairs. Monath is also a Venture Partner at Kleiner Perkins Caufield & Byers and Adjunct Professor, Harvard School of Public Health.

14



Emilio Emini,
Senior Vice President and Chief
Scientific Officer Vaccine Research,
Pfizer

Emilio A. Emini, Ph.D., is Senior Vice President and Chief Scientific Officer of Vaccine Research at Pfizer Inc., a position into which he transitioned subsequent to Pfizer's acquisition of Wyeth Pharmaceuticals in late 2009. Dr. Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005. At Wyeth, he led the R&D efforts that resulted in licensure of our second-generation vaccine for the prevention of pneumococcal disease.

13



Steven Reed,
President & Founder,
IDRI

Steve Reed is the Founder, President, and CSO of the Infectious Disease Research Institute (IDRI). His academic appointments include Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health, and is a member of the Vaccine Development Steering Committee of the World Health Organization.

12



Walter Orenstein,
Professor of medicine, global health,
and pediatrics,
Emory University

From 2008 through 2011, Dr. Orenstein was deputy director for Immunization Programs in the Vaccine Delivery Department of the Global Health Program at the Bill & Melinda Gates Foundation. His primary focus at the foundation had been on polio eradication, measles control, and improving routine immunization programs. Between 2004 and 2008, he was professor of medicine and pediatrics at Emory University, associate director of the Emory Vaccine Center, and director of the Emory Program on Vaccine Policy and Development among other responsibilities.

11



Gary Nabel,
Chair, Strategic Development and
Scientific Advisory Council,
Sanofi

Dr Nabel joined Sanofi as chief scientific officer in November 2012, having previously served as director of the vaccine research centre (VRC) of the NIAID. He provided overall direction and scientific leadership of the basic, clinical, and translational research activities of the VRC and guided development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases, including Ebola/Marburg hemorrhagic fevers, influenza, chikungunya and other viruses.

10



Gordon Dougan,
Member of the Board of
Management,
Wellcome Trust Sanger Institute

He is also an Honorary Professor at Cambridge University and a Fellow of Wolfson College. He represents the area of Pathogens on the WTSI Board of Management. His personal research team studies enteric pathogens with a strong emphasis on basic pathogenic mechanisms and immunology and he is involved in the Mouse Genetic Programme running an infection screen in novel KO strains.

9



Ciro de Quadros,
Executive Vice President, Director of
Vaccine Advocacy and Education
Sabin Vaccine Institute

Before joining Sabin in 2003, Dr. de Quadros was the Director of the Division of Vaccines and Immunization at the Pan American Health Organization. He also served as the World Health Organization's Chief Epidemiologist for the Smallpox Eradication Program in Ethiopia from 1970 to 1976.

8



Ted Bianco,
Acting Director,
Wellcome Trust

Ted Bianco joined the Trust in 1999 as Head of the Centres and Initiatives department and became Director of Technology Transfer in 2002. Before joining the Trust, Ted was the Professor of Parasitology at the Liverpool School of Tropical Medicine where he led a research group working on the immunobiology of filarial infections. The Wellcome Trust, appointed Ted Bianco as its acting director in Feb 2013. Bianco, the charity's director of technology transfer, will take the helm on 14 March, when current director Mark Walport departs.

7



Suresh Jadhav,
Executive Director,
Serum Institute India

Serum Institute of India is one of the largest vaccine manufacturers from the developing countries, supplying vaccines at affordable prices. Dr. Jadhav is associated with the DCVM since its inception in 2000. He is currently a member of GAVI Board, EVI Board of Stakeholders, FastVac, besides a member of the Program & Policy Committee of GAVI. He is also associated with various advisory committees/Task Force of Sabin Vaccine Institute, WHO IVR and Decades of Vaccines – Protection & Synergies Group etc.

6



Paul Offit,
Director, Vaccine Education Center,
Children's Hospital of Philadelphia

Paul A. Offit is an American pediatrician specializing in infectious diseases and an expert on vaccines, immunology, and virology. He is the co-inventor of a rotavirus vaccine that has been credited with saving hundreds of lives every day.

5

**Seth Berkley,
CEO,
GAVI Alliance**

Seth Franklin Berkley, M.D. is a medical epidemiologist by training. He is the CEO of the GAVI Alliance and a global advocate on the power of vaccines. He is also the founder and former President and CEO of the International AIDS Vaccine Initiative.

Dr Berkley brings to GAVI a wealth of experience as an entrepreneurial CEO and fundraiser and a proven ability in building coalitions around a common vision. Under his leadership, IAVI implemented a global advocacy programme that assured that vaccines receive prominent attention in the media and in political fora such as the G8, EU and the UN. He also oversaw the creation of a virtual vaccine product development effort involving industry, academia, and developing country scientists.

Prior to founding IAVI in 1996, Dr Berkley was an officer of the Health Sciences Division at The Rockefeller Foundation where he managed programmes on vaccines, AIDS, reproductive health and public health training in Africa, Asia and Latin America. His past experience also includes work at the U.S. Centers for Disease Control and the Task Force for Child Survival at the Carter Center where he served as the Ministry of Health Epidemiologist in Uganda.



4 **Melinda Gates,** Co-Chair and Trustee, **Bill & Melinda Gates Foundation**

Melinda French Gates is an American businesswoman and philanthropist. The Bill and Melinda Gates Foundation is financially backing and publicly endorsing mass polio virus vaccinations in India.

Every year, 2.4 million children die from preventable diseases despite the availability of effective vaccines. Millions more survive, but they're left severely impaired. The long-range effects of childhood illnesses hinder the ability of those who survive to become educated, work, or care for themselves or others. This puts a strain on their families and on the economies of developing countries.

Getting cost-effective vaccines to the people who need them is complicated. Successfully delivering high-quality vaccines requires a comprehensive temperature-controlled delivery system called the "cold chain." Vaccines need to be transported at the correct temperature to prevent them from either freezing or being exposed to too much heat. But in many countries, it's difficult to ensure this type of transport from the airport to the children in the village who need the vaccines.

We believe that a coordinated effort to develop and distribute underused and new vaccines can save millions of lives. Success will be achieved through the coordinated efforts of national governments, their global development partners, pharmaceutical companies, non-governmental organizations, community health workers, and parents.




3 Rino Rappuoli, Head of Research & Development, Novartis Vaccines

Rino Rappuoli is Global Head of Vaccines Research at Novartis Vaccines and Diagnostics and is based in Siena, Italy. He earned his PhD in Biological Sciences at the University of Siena and has served as visiting scientist at Rockefeller University in New York and Harvard Medical School in Boston. Prior to the present position he was head R&D of Sclavo and then head of vaccine research and Chief Scientific Officer of Chiron Corporation.

Several molecules he worked with became part, or are near to becoming, licensed vaccines. These include: CRM197 used in H. influenzae, N. meningitidis and pneumococcus vaccines; an acellular vaccine against pertussis containing a genetically detoxified pertussis toxin; the first conjugate vaccine against meningococcus C and later against meningococcus ACYW; the MF59 used in a vaccine against pandemic influenza; and the genome-derived vaccine against meningococcus B currently under review by European and Canadian regulatory agencies.

He was elected member of the US National Academy of Sciences and the European Molecular Biology Organization. Awards conferred include: Paul Ehrlich and Ludwig Darmstaedter Prize (1991), the Gold Medal by the Italian President (2005), the Albert B. Sabin Gold Medal (2009), the Lifetime Achievement Award from the Institute of Human Virology in Maryland (2010), and the Excellence Award from the European Society of Clinical Microbiology and Infectious Diseases (2011).



2 Stan Plotkin,
Emeritus Prof, **Uni of Pennsylvania &**
Adjunct Prof,
Johns Hopkins University

Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. Then he left the University to join the vaccine Pasteur-Mérieux-Connaught, where for seven years he was Medical and Scientific Director. The same company is now named Sanofi Pasteur. He is now consultant to vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult, LLC.

Dr. Plotkin attended New York University, where he received a B.A. degree, and then the State University of New York Medical School in Brooklyn, where he received an M.D. degree in 1956. His subsequent career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children's Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service.



1 **Bill Gates,** Co-Chair and Trustee, **Bill & Melinda Gates Foundation**

Bill Gates is co-chair of the Bill & Melinda Gates Foundation. Along with co-chair Melinda Gates, he shapes and approves grant making strategies, advocates for the foundation's issues, and helps set the overall direction of the organization.

Bill and Melinda Gates work together to expand opportunity to the world's most disadvantaged people by collaborating with grantees and partners.

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. Vaccines have played a major role in the foundation's supported initiatives. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life.



We'd love to hear your views on all of this...

Join the conversation



[Click here](#) to leave a comment on this page on the Vaccine Nation blog



[Click here](#) to contribute to our LinkedIn discussion



[Click here](#) to follow us on Twitter @vaccination



[Click here](#) to sign up for the Vaccine Nation blog e-newsletter for more updates on strategy and innovation in vaccines

We'd love to meet you too...

The World Vaccine Congress & Expo is now in its 13th year. It is the world's biggest and most comprehensive event for the vaccine industry.

Over 60% of our attendees come from the world's leading pharma and biotechs.

Our expo market place is the only one of its kind for the vaccine industry.

Combining a high level conference with a focused exhibition and adding in guaranteed meetings with targeted buyers in a 1-2-1 Partnering format makes this event the one must-attend event for the whole vaccine market.

To learn more about the World Vaccine Congress, visit the website.

Be sure to check out our blog for more information about strategy and innovation in vaccines.



vaccinenation

Strategy and innovation in vaccines

terrapinn.com/vaccines